Biodexa Pharmaceuticals Plc (NASDAQ:BDRX – Get Free Report) was the recipient of a large decrease in short interest in the month of May. As of May 15th, there was short interest totalling 322,000 shares, a decrease of 84.4% from the April 30th total of 2,060,000 shares. Based on an average daily volume of 4,960,000 shares, […]
Biodexa Pharmaceuticals PLC announced that results of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis are scheduled for presentation at the prestigious 2024 Digestive Disease.